Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to 0.65%.

  • ImmunityBio's Return on Capital Employed rose 4000.0% to 0.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.65%, marking a year-over-year increase of 4000.0%. This contributed to the annual value of 0.89% for FY2024, which is 800.0% up from last year.
  • Latest data reveals that ImmunityBio reported Return on Capital Employed of 0.65% as of Q3 2025, which was up 4000.0% from 0.94% recorded in Q2 2025.
  • ImmunityBio's 5-year Return on Capital Employed high stood at 14.9% for Q2 2022, and its period low was 7.05% during Q1 2022.
  • In the last 5 years, ImmunityBio's Return on Capital Employed had a median value of 1.0% in 2024 and averaged 0.53%.
  • As far as peak fluctuations go, ImmunityBio's Return on Capital Employed surged by 166500bps in 2022, and later plummeted by -136400bps in 2023.
  • Over the past 5 years, ImmunityBio's Return on Capital Employed (Quarter) stood at 12.09% in 2021, then plummeted by -80bps to 2.45% in 2022, then crashed by -136bps to 0.88% in 2023, then fell by -22bps to 1.08% in 2024, then soared by 40bps to 0.65% in 2025.
  • Its Return on Capital Employed stands at 0.65% for Q3 2025, versus 0.94% for Q2 2025 and 1.07% for Q1 2025.